Clinical  ||| S:0 E:9 ||| JJ
trial  ||| S:9 E:15 ||| NN
experience  ||| S:15 E:26 ||| NN
with  ||| S:26 E:31 ||| IN
temsirolimus  ||| S:31 E:44 ||| NN
in  ||| S:44 E:47 ||| IN
patients  ||| S:47 E:56 ||| NNS
with  ||| S:56 E:61 ||| IN
advanced  ||| S:61 E:70 ||| JJ
renal  ||| S:70 E:76 ||| JJ
cell  ||| S:76 E:81 ||| NN
carcinoma  ||| S:81 E:91 ||| VBZ
Clinical  ||| S:91 E:100 ||| JJ
trials  ||| S:100 E:107 ||| NNS
have  ||| S:107 E:112 ||| VBP
validated  ||| S:112 E:122 ||| VBG
the  ||| S:122 E:126 ||| DT
importance  ||| S:126 E:137 ||| NN
of  ||| S:137 E:140 ||| IN
mammalian  ||| S:140 E:150 ||| JJ
target  ||| S:150 E:157 ||| NN
of  ||| S:157 E:160 ||| IN
rapamycin  ||| S:160 E:170 ||| NNS
( ||| S:170 E:171 ||| -LRB-
mTOR ||| S:171 E:175 ||| NNP
)  ||| S:175 E:177 ||| -RRB-
as  ||| S:177 E:180 ||| IN
a  ||| S:180 E:182 ||| DT
therapeutic  ||| S:182 E:194 ||| JJ
target  ||| S:194 E:201 ||| NN
in  ||| S:201 E:204 ||| IN
patients  ||| S:204 E:213 ||| NNS
with  ||| S:213 E:218 ||| IN
advanced  ||| S:218 E:227 ||| JJ
renal  ||| S:227 E:233 ||| JJ
cell  ||| S:233 E:238 ||| NN
carcinoma  ||| S:238 E:248 ||| NNS
( ||| S:248 E:249 ||| -LRB-
RCC ||| S:249 E:252 ||| NNP
) ||| S:252 E:253 ||| -RRB-
.  ||| S:253 E:255 ||| .
The  ||| S:255 E:259 ||| DT
TORC1  ||| S:259 E:265 ||| JJ
complex  ||| S:265 E:273 ||| JJ
controls  ||| S:273 E:282 ||| NNS
translation  ||| S:282 E:294 ||| NN
of  ||| S:294 E:297 ||| IN
key  ||| S:297 E:301 ||| JJ
proteins  ||| S:301 E:310 ||| NNS
involved  ||| S:310 E:319 ||| VBN
in  ||| S:319 E:322 ||| IN
cell  ||| S:322 E:327 ||| NN
proliferation  ||| S:327 E:341 ||| NN
and  ||| S:341 E:345 ||| CC
regulates  ||| S:345 E:355 ||| VBZ
the  ||| S:355 E:359 ||| DT
expression  ||| S:359 E:370 ||| NN
and  ||| S:370 E:374 ||| CC
stability  ||| S:374 E:384 ||| NN
of  ||| S:384 E:387 ||| IN
hypoxia-inducible  ||| S:387 E:405 ||| JJ
factor  ||| S:405 E:412 ||| NN
( ||| S:412 E:413 ||| -LRB-
HIF ||| S:413 E:416 ||| NNP
) ||| S:416 E:417 ||| -RRB-
-1alpha ||| S:417 E:424 ||| NNP
.  ||| S:424 E:426 ||| .
Temsirolimus ||| S:426 E:438 ||| NNP
,  ||| S:438 E:440 ||| ,
the  ||| S:440 E:444 ||| DT
first  ||| S:444 E:450 ||| JJ
mTOR  ||| S:450 E:455 ||| JJ
inhibitor  ||| S:455 E:465 ||| NNS
approved  ||| S:465 E:474 ||| VBN
for  ||| S:474 E:478 ||| IN
treatment  ||| S:478 E:488 ||| NN
of  ||| S:488 E:491 ||| IN
advanced  ||| S:491 E:500 ||| JJ
RCC ||| S:500 E:503 ||| NNP
,  ||| S:503 E:505 ||| ,
has  ||| S:505 E:509 ||| VBZ
demonstrated  ||| S:509 E:522 ||| VBN
significantly  ||| S:522 E:536 ||| RB
longer  ||| S:536 E:543 ||| RBR
overall  ||| S:543 E:551 ||| JJ
survival  ||| S:551 E:560 ||| NN
( ||| S:560 E:561 ||| -LRB-
hazard  ||| S:561 E:568 ||| NN
ratio  ||| S:568 E:574 ||| NN
for  ||| S:574 E:578 ||| IN
death ||| S:578 E:583 ||| NN
,  ||| S:583 E:585 ||| ,
0.73 ||| S:585 E:589 ||| CD
;  ||| S:589 E:591 ||| :
95 ||| S:591 E:593 ||| CD
%  ||| S:593 E:595 ||| NN
confidence  ||| S:595 E:606 ||| NN
interval ||| S:606 E:614 ||| NN
,  ||| S:614 E:616 ||| ,
0.58-0.92 ||| S:616 E:625 ||| NNP
,  ||| S:625 E:627 ||| ,
P  ||| S:627 E:629 ||| NN
=  ||| S:629 E:631 ||| SYM
.008 ||| S:631 E:635 ||| CD
)  ||| S:635 E:637 ||| -RRB-
and  ||| S:637 E:641 ||| CC
progression-free  ||| S:641 E:658 ||| JJ
survival  ||| S:658 E:667 ||| NN
( ||| S:667 E:668 ||| -LRB-
P  ||| S:668 E:670 ||| NNP
< ||| S:670 E:671 ||| SYM
.001 ||| S:671 E:675 ||| NNP
)  ||| S:675 E:677 ||| -RRB-
compared  ||| S:677 E:686 ||| VBN
with  ||| S:686 E:691 ||| IN
interferon  ||| S:691 E:702 ||| JJ
alfa  ||| S:702 E:707 ||| NNS
( ||| S:707 E:708 ||| -LRB-
IFN ||| S:708 E:711 ||| NNP
)  ||| S:711 E:713 ||| -RRB-
for  ||| S:713 E:717 ||| IN
patients  ||| S:717 E:726 ||| NNS
with  ||| S:726 E:731 ||| IN
poor  ||| S:731 E:736 ||| JJ
prognostic  ||| S:736 E:747 ||| JJ
features ||| S:747 E:755 ||| NNS
.  ||| S:755 E:757 ||| .
Median  ||| S:757 E:764 ||| JJ
progression-free  ||| S:764 E:781 ||| JJ
survival  ||| S:781 E:790 ||| NN
durations  ||| S:790 E:800 ||| NNS
were  ||| S:800 E:805 ||| VBD
3.8  ||| S:805 E:809 ||| CD
and  ||| S:809 E:813 ||| CC
1.9  ||| S:813 E:817 ||| CD
months ||| S:817 E:823 ||| NNS
,  ||| S:823 E:825 ||| ,
respectively ||| S:825 E:837 ||| RB
,  ||| S:837 E:839 ||| ,
for  ||| S:839 E:843 ||| IN
patients  ||| S:843 E:852 ||| NNS
treated  ||| S:852 E:860 ||| VBN
with  ||| S:860 E:865 ||| IN
temsirolimus  ||| S:865 E:878 ||| NN
or  ||| S:878 E:881 ||| CC
IFN ||| S:881 E:884 ||| NNP
,  ||| S:884 E:886 ||| ,
and  ||| S:886 E:890 ||| CC
median  ||| S:890 E:897 ||| JJ
overall  ||| S:897 E:905 ||| JJ
survivals  ||| S:905 E:915 ||| NN
were  ||| S:915 E:920 ||| VBD
10.9  ||| S:920 E:925 ||| CD
and  ||| S:925 E:929 ||| CC
7.3  ||| S:929 E:933 ||| CD
months ||| S:933 E:939 ||| NNS
,  ||| S:939 E:941 ||| ,
respectively ||| S:941 E:953 ||| RB
.  ||| S:953 E:955 ||| .
Exploratory  ||| S:955 E:967 ||| JJ
analyses  ||| S:967 E:976 ||| NNS
indicate  ||| S:976 E:985 ||| VBP
that  ||| S:985 E:990 ||| IN
temsirolimus  ||| S:990 E:1003 ||| JJ
benefits  ||| S:1003 E:1012 ||| NNS
those  ||| S:1012 E:1018 ||| DT
patients  ||| S:1018 E:1027 ||| NNS
with  ||| S:1027 E:1032 ||| IN
metastatic  ||| S:1032 E:1043 ||| JJ
RCC  ||| S:1043 E:1047 ||| NNP
and  ||| S:1047 E:1051 ||| CC
multiple  ||| S:1051 E:1060 ||| JJ
adverse  ||| S:1060 E:1068 ||| JJ
prognostic  ||| S:1068 E:1079 ||| JJ
factors  ||| S:1079 E:1087 ||| NNS
regardless  ||| S:1087 E:1098 ||| RB
of  ||| S:1098 E:1101 ||| IN
tumor  ||| S:1101 E:1107 ||| NN
histology  ||| S:1107 E:1117 ||| NNS
or  ||| S:1117 E:1120 ||| CC
nephrectomy  ||| S:1120 E:1132 ||| JJ
status ||| S:1132 E:1138 ||| NN
.  ||| S:1138 E:1140 ||| .
Most  ||| S:1140 E:1145 ||| RBS
adverse  ||| S:1145 E:1153 ||| JJ
events  ||| S:1153 E:1160 ||| NNS
that  ||| S:1160 E:1165 ||| WDT
occur  ||| S:1165 E:1171 ||| VBP
in  ||| S:1171 E:1174 ||| IN
patients  ||| S:1174 E:1183 ||| NNS
receiving  ||| S:1183 E:1193 ||| VBG
temsirolimus  ||| S:1193 E:1206 ||| NNS
can  ||| S:1206 E:1210 ||| MD
be  ||| S:1210 E:1213 ||| VB
managed  ||| S:1213 E:1221 ||| VBN
medically  ||| S:1221 E:1231 ||| NNS
( ||| S:1231 E:1232 ||| -LRB-
eg ||| S:1232 E:1234 ||| UH
,  ||| S:1234 E:1236 ||| ,
hyperglycemia ||| S:1236 E:1249 ||| NN
,  ||| S:1249 E:1251 ||| ,
hyperlipidemia ||| S:1251 E:1265 ||| CD
)  ||| S:1265 E:1267 ||| -RRB-
or  ||| S:1267 E:1270 ||| CC
addressed  ||| S:1270 E:1280 ||| VBN
by  ||| S:1280 E:1283 ||| IN
supportive  ||| S:1283 E:1294 ||| JJ
measures  ||| S:1294 E:1303 ||| NNS
( ||| S:1303 E:1304 ||| -LRB-
eg ||| S:1304 E:1306 ||| UH
,  ||| S:1306 E:1308 ||| ,
stomatitis ||| S:1308 E:1318 ||| NN
,  ||| S:1318 E:1320 ||| ,
rash ||| S:1320 E:1324 ||| NN
) ||| S:1324 E:1325 ||| -RRB-
.  ||| S:1325 E:1327 ||| .
Although  ||| S:1327 E:1336 ||| IN
development  ||| S:1336 E:1348 ||| NN
of  ||| S:1348 E:1351 ||| IN
symptomatic  ||| S:1351 E:1363 ||| JJ
pneumonitis  ||| S:1363 E:1375 ||| NN
is  ||| S:1375 E:1378 ||| VBZ
rare ||| S:1378 E:1382 ||| JJ
,  ||| S:1382 E:1384 ||| ,
monitoring  ||| S:1384 E:1395 ||| NN
is  ||| S:1395 E:1398 ||| VBZ
recommended ||| S:1398 E:1409 ||| VBN
.  ||| S:1409 E:1411 ||| .
Temsirolimus  ||| S:1411 E:1424 ||| NNP
is  ||| S:1424 E:1427 ||| VBZ
now  ||| S:1427 E:1431 ||| RB
considered  ||| S:1431 E:1442 ||| VBN
an  ||| S:1442 E:1445 ||| DT
important  ||| S:1445 E:1455 ||| JJ
first-line  ||| S:1455 E:1466 ||| JJ
treatment  ||| S:1466 E:1476 ||| NN
option  ||| S:1476 E:1483 ||| NN
for  ||| S:1483 E:1487 ||| IN
patients  ||| S:1487 E:1496 ||| NNS
with  ||| S:1496 E:1501 ||| IN
advanced  ||| S:1501 E:1510 ||| JJ
RCC  ||| S:1510 E:1514 ||| NNP
and  ||| S:1514 E:1518 ||| CC
multiple  ||| S:1518 E:1527 ||| JJ
factors  ||| S:1527 E:1535 ||| NNS
predictive  ||| S:1535 E:1546 ||| VBN
of  ||| S:1546 E:1549 ||| IN
short  ||| S:1549 E:1555 ||| JJ
survival ||| S:1555 E:1563 ||| NN
.  ||| S:1563 E:1565 ||| .
Current  ||| S:1565 E:1573 ||| JJ
trials  ||| S:1573 E:1580 ||| NNS
are  ||| S:1580 E:1584 ||| VBP
investigating  ||| S:1584 E:1598 ||| VBG
the  ||| S:1598 E:1602 ||| DT
use  ||| S:1602 E:1606 ||| NN
of  ||| S:1606 E:1609 ||| IN
temsirolimus  ||| S:1609 E:1622 ||| NN
in  ||| S:1622 E:1625 ||| IN
sequence  ||| S:1625 E:1634 ||| NN
or  ||| S:1634 E:1637 ||| CC
in  ||| S:1637 E:1640 ||| IN
combination  ||| S:1640 E:1652 ||| NN
with  ||| S:1652 E:1657 ||| IN
other  ||| S:1657 E:1663 ||| JJ
targeted  ||| S:1663 E:1672 ||| JJ
agents  ||| S:1672 E:1679 ||| NNS
to  ||| S:1679 E:1682 ||| TO
further  ||| S:1682 E:1690 ||| RB
improve  ||| S:1690 E:1698 ||| VB
outcomes ||| S:1698 E:1706 ||| NNS
.  ||| S:1706 E:1708 ||| .
